These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27499099)

  • 21. Characterization of CD44+ALDH1+Ki-67- Cells in Non-malignant and Neoplastic Lesions of the Breast.
    DA Cruz Paula A; Marques O; Sampaio R; Rosa A; Garcia J; Rêma A; DE Fátima Faria M; Silva P; Vizcaíno R; Lopes C
    Anticancer Res; 2016 Sep; 36(9):4629-38. PubMed ID: 27630305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis.
    Fujiwara S; Ibusuki M; Yamamoto S; Yamamoto Y; Iwase H
    Breast Cancer; 2014 Jul; 21(4):472-81. PubMed ID: 23100016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
    Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
    Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased HCRP1 expression is associated with poor prognosis in breast cancer patients.
    Xu J; Yang W; Wang Q; Zhang Q; Li X; Lin X; Liu X; Qin Y
    Int J Clin Exp Pathol; 2014; 7(11):7915-22. PubMed ID: 25550832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding the dual nature of CD44 in breast cancer progression.
    Louderbough JM; Schroeder JA
    Mol Cancer Res; 2011 Dec; 9(12):1573-86. PubMed ID: 21970856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer.
    Gwak JM; Kim HJ; Kim EJ; Chung YR; Yun S; Seo AN; Lee HJ; Park SY
    Breast Cancer Res Treat; 2014 Aug; 147(1):39-49. PubMed ID: 25086633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P-gp substrates in vitro and in vivo.
    Jin Y; Zhang W; Wang H; Zhang Z; Chu C; Liu X; Zou Q
    Oncol Rep; 2016 Feb; 35(2):771-8. PubMed ID: 26718028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
    Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
    Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells.
    Dhillon J; Astanehe A; Lee C; Fotovati A; Hu K; Dunn SE
    Oncogene; 2010 Nov; 29(47):6294-300. PubMed ID: 20802512
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
    Rydén L; Jirström K; Haglund M; Stål O; Fernö M
    Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast.
    Oon ML; Thike AA; Tan SY; Tan PH
    Breast Cancer Res Treat; 2015 Feb; 150(1):31-41. PubMed ID: 25677743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
    Nassar A; Sussman ZM; Lawson D; Cohen C
    Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
    Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
    J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristic genes in luminal subtype breast tumors with CD44+CD24-/low gene expression signature.
    Tsunoda Y; Sakamoto M; Sawada T; Sasaki A; Yamamoto G; Tachikawa T
    Oncology; 2011; 81(5-6):336-44. PubMed ID: 22237177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
    Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
    PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Malignant peripheral nerve sheath tumor cell invasion is facilitated by Src and aberrant CD44 expression.
    Su W; Sin M; Darrow A; Sherman LS
    Glia; 2003 Jun; 42(4):350-8. PubMed ID: 12730955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer.
    Kobayashi K; Matsumoto H; Matsuyama H; Fujii N; Inoue R; Yamamoto Y; Nagao K
    Oncol Rep; 2016 Nov; 36(5):2852-2860. PubMed ID: 27599396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD44 regulates cell proliferation, migration, and invasion via modulation of c-Src transcription in human breast cancer cells.
    Nam K; Oh S; Lee KM; Yoo SA; Shin I
    Cell Signal; 2015 Sep; 27(9):1882-94. PubMed ID: 25979842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients.
    Cheng Y; Tao L; Xu J; Li Q; Yu J; Jin Y; Chen Q; Xu Z; Zou Q; Liu X
    Mol Carcinog; 2014 Sep; 53(9):686-97. PubMed ID: 23681900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.